Sumatriptan causes parallel decrease in plasma calcitonin gene-related peptide (CGRP) concentration and migraine headache during nitroglycerin induced migraine attack - PubMed (original) (raw)

Clinical Trial

Sumatriptan causes parallel decrease in plasma calcitonin gene-related peptide (CGRP) concentration and migraine headache during nitroglycerin induced migraine attack

G Juhasz et al. Cephalalgia. 2005 Mar.

Abstract

Sumatriptan-induced changes in plasma calcitonin gene-related peptide (CGRP) concentration and headache intensity were investigated in 19 female migraineurs during nitroglycerin-induced migraine attack. Sumatriptan nasal spray was administered 120 min after the onset of the attack. Blood samples were obtained immediately before and 60 min after sumatriptan administration. In those subjects whose migraine attack improved considerably 60 min after the treatment the plasma CGRP concentration decreased significantly (P<0.05). In contrast, plasma CGRP concentration failed to change in patients whose headache did not improve. In addition, plasma CGRP concentrations showed significant positive correlations with the headache scores both 60 and 120 min after sumatriptan administration (P<0.05). According to our results plasma CGRP concentration decreases parallel to headache intensity during sumatriptan treatment and this decrease in CGRP predicts effectiveness of antimigraine drug therapy. This supports that one of the main effects of triptans is to decrease CGRP release.

PubMed Disclaimer

Similar articles

• Sumatriptan causes parallel decrease in plasma CGRP concentration and migraine headache during nitroglycerin-induced migraine attack.
  Vanmolkot F, Van der Schueren B, de Hoon J. Vanmolkot F, et al. Cephalalgia. 2006 Aug;26(8):1037-8; author reply 1038-9. doi: 10.1111/j.1468-2982.2006.01133_1.x. Cephalalgia. 2006. PMID: 16886948 No abstract available.
• NO-induced migraine attack: strong increase in plasma calcitonin gene-related peptide (CGRP) concentration and negative correlation with platelet serotonin release.
  Juhasz G, Zsombok T, Modos EA, Olajos S, Jakab B, Nemeth J, Szolcsanyi J, Vitrai J, Bagdy G. Juhasz G, et al. Pain. 2003 Dec;106(3):461-470. doi: 10.1016/j.pain.2003.09.008. Pain. 2003. PMID: 14659530
• Calcitonin gene-related peptide (CGRP) levels during glyceryl trinitrate (GTN)-induced headache in healthy volunteers.
  Kruuse C, Iversen HK, Jansen-Olesen I, Edvinsson L, Olesen J. Kruuse C, et al. Cephalalgia. 2010 Apr;30(4):467-74. doi: 10.1111/j.1468-2982.2009.01963.x. Epub 2010 Feb 11. Cephalalgia. 2010. PMID: 19673898 Clinical Trial.
• [Pharmacologic treatment of acute migraine attack in children].
  Cuvellier JC, Joriot S, Auvin S, Vallée L. Cuvellier JC, et al. Arch Pediatr. 2005 Mar;12(3):316-25. doi: 10.1016/j.arcped.2004.10.012. Arch Pediatr. 2005. PMID: 15734131 Review. French.

Cited by

• Discovery and validation of biomarkers to aid the development of safe and effective pain therapeutics: challenges and opportunities.
  Davis KD, Aghaeepour N, Ahn AH, Angst MS, Borsook D, Brenton A, Burczynski ME, Crean C, Edwards R, Gaudilliere B, Hergenroeder GW, Iadarola MJ, Iyengar S, Jiang Y, Kong JT, Mackey S, Saab CY, Sang CN, Scholz J, Segerdahl M, Tracey I, Veasley C, Wang J, Wager TD, Wasan AD, Pelleymounter MA. Davis KD, et al. Nat Rev Neurol. 2020 Jul;16(7):381-400. doi: 10.1038/s41582-020-0362-2. Epub 2020 Jun 15. Nat Rev Neurol. 2020. PMID: 32541893 Free PMC article. Review.
• Molecular Mechanisms of Migraine: Nitric Oxide Synthase and Neuropeptides.
  Karsan N, Gosalia H, Goadsby PJ. Karsan N, et al. Int J Mol Sci. 2023 Jul 26;24(15):11993. doi: 10.3390/ijms241511993. Int J Mol Sci. 2023. PMID: 37569369 Free PMC article. Review.
• Models of Trigeminal Activation: Is There an Animal Model of Migraine?
  Spekker E, Fejes-Szabó A, Nagy-Grócz G. Spekker E, et al. Brain Sci. 2024 Mar 27;14(4):317. doi: 10.3390/brainsci14040317. Brain Sci. 2024. PMID: 38671969 Free PMC article. Review.
• The Potentials of Uncariae Ramulus Cum Uncis for the Treatment of Migraine: Targeting CGRP in the Trigeminovascular System.
  Chong CM, Zhong Z, Vong CT, Wang S, Lu JJ, Zhong HJ, Su H, Wang Y. Chong CM, et al. Curr Neuropharmacol. 2021;19(7):1090-1100. doi: 10.2174/1570159X18666201029150937. Curr Neuropharmacol. 2021. PMID: 33121411 Free PMC article. Review.
• A novel CGRP-neutralizing Spiegelmer attenuates neurogenic plasma protein extravasation.
  Hoehlig K, Johnson KW, Pryazhnikov E, Maasch C, Clemens-Smith A, Purschke WG, Vauléon S, Buchner K, Jarosch F, Khiroug L, Vater A, Klussmann S. Hoehlig K, et al. Br J Pharmacol. 2015 Jun;172(12):3086-98. doi: 10.1111/bph.13110. Epub 2015 Mar 27. Br J Pharmacol. 2015. PMID: 25659966 Free PMC article.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Atypon
  • Ovid Technologies, Inc.

• Other Literature Sources

  • The Lens - Patent Citations Database

• Research Materials

  • NCI CPTC Antibody Characterization Program